Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track TAK with free AI briefings, catalyst countdowns, and dilution alerts.

TAK · TAKEDA PHARMACEUTICAL CO LTD

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$418.5B Cash on Hand
CF+ Cash Runway
Follow TAK by email Get an email when TAK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about TAK, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vedolizumab
FDA approved May 2014 · Entyvio
Crohn's Disease Phase 4 · NCT06045754 Active not recruiting
Mobocertinib (TAK-788)
FDA approved Sep 2021 · Exkivity (discontinued)
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Phase 3 · NCT04129502 Completed
Vortioxetine
FDA approved Sep 2013 · Trintellix
Major Depressive Disorder Phase 3 · NCT07204314 Recruiting
Ponatinib
FDA approved Dec 2012 · Iclusig
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Phase 2 · NCT03263572 Recruiting
Brigatinib
FDA approved Apr 2017 · Alunbrig
Neurofibromatosis Type 2 Phase 2 · NCT04374305 Recruiting
Ixazomib
FDA approved Nov 2015 · Ninlaro
HIV (Human Immunodeficiency Virus) Phase 2 · NCT07881809 Not yet recruiting
Maribavir
FDA approved Nov 2021 · Livtencity
Cytomegalovirus (CMV) N/A · NCT06555432 Recruiting
TAK-360 Idiopathic Hypersomnia Phase 2/3 · NCT07646678 Recruiting
TAK-279 Generalized Pustular Psoriasis Phase 3 · NCT06323356 Completed
TAK-861 Narcolepsy Type 1 (NT1) Phase 3 · NCT07363720 Active not recruiting
Mezagitamab Immune Thrombocytopenic Purpura (ITP) Phase 3 · NCT06948318 Recruiting
Eptacog Alfa Hemophilia A Phase 3 · NCT04563520 Withdrawn
Anti-Inhibitor Coagulant Complex Hemophilia A Phase 3 · NCT04563520 Withdrawn
Fazirsiran Alpha1-Antitrypsin Deficiency Phase 3 · NCT05899673 Active not recruiting
Elritercept Myelodysplastic Syndrome Phase 3 · NCT07422480 Recruiting
TAK-928 IO Resistant Squamous and Nonsquamous NSCLC Phase 3 · NCT07217301 Recruiting

Also used in these trials (approved or third-party drugs, not TAK's own candidates): Adalimumab, Tofacitinib, Ustekinumab, Pemetrexed Disodium, Emicizumab, Epoetin Alfa, Cisplatin, Carboplatin, Retifanlimab, Bevacizumab, Blinatumomab, Brentuximab Vedotin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

TAK holds $418.5B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TAK files for a raise →

👥 Who Owns TAK

Insiders 0.2% Other 5%+ holders 0.6% Institutions (468 holders) 3.3% Public and other holders 95.9%
HolderTypeShares% of sharesAs of
Takeda Pharmaceutical Company Limited 5%+ holder (13G) 8,781,996 0.56% 2025-12-08
Andrew Stewart Plump
President, R&D, Director
Insider 912,034 0.06% 2026-09-02
Julie So-Young Kim
President and CEO, Director
Insider 391,489 0.03% 2026-08-10
Giles Richard Platford
President, IBU
Insider 270,253 0.02% 2026-11-04
Teresa Marie Bitetti
President, OBU
Insider 214,501 0.01% 2026-11-02
Natalie Anne Marie Furney
Global General Counsel
Insider 204,298 0.01% 2026-08-10
Lauren Rusckowski Duprey
Chief Transformation Officer
Insider 191,522 0.01% 2026-09-14
Rhonda Janice Pacheco
President, U.S. Business Unit
Insider 182,507 0.01% 2026-08-10
Agosti Marcello Pignagnoli
Head, Strat. & Port. Dev
Insider 176,977 0.01% 2026-08-10
Gabriele Ricci
Chief Data & Tech. Officer
Insider 171,654 0.01% 2026-08-10
Awny Samaan Botros Farajallah
Chief Medical Officer
Insider 116,177 0.01% 2026-08-10
Ramy Riad Ahmed Ibrahim
President, PDT BU
Insider 102,588 0.01% 2026-08-10

Share count 1,557,765,596 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full TAK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TAK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.